| |
All pharmaceutical companies (Number of drugs, (%))
|
Top 20 leading companies (Number of drugs, (%))
|
Percentage of top 20 companies
|
|---|
|
Total
|
10,550 (100)
|
2669 (100)
|
25.3%
|
|
Phase
|
|
Discovery
|
1406 (13.3)
|
260 (9.7)
|
18.5%
|
|
Preclinical
|
2979 (28.2)
|
275 (10.3)
|
9.2%
|
|
Clinicals
|
144 (1.4)
|
7 (0.3)
|
4.9%
|
|
Phase I
|
1794 (17)
|
523 (19.6)
|
29.2%
|
|
Phase II
|
1936 (18.4)
|
482 (18.1)
|
24.9%
|
|
Phase III
|
817 (7.7)
|
230 (8.6)
|
28.2%
|
|
Pre-registration
|
168 (1.6)
|
46 (1.7)
|
27.4%
|
|
Registered
|
146 (1.4)
|
37 (1.4)
|
25.3%
|
|
Marketed
|
1070 (10.1)
|
754 (28.3)
|
70.5%
|
|
N/A (Technology)
|
90 (0.9)
|
55 (2.1)
|
61.1%
|
|
Orphan drugsa
|
1076 (10.2)
|
355 (13.3)
|
33.0%
|
|
Biologic productsb
|
4905 (46.5)
|
1165 (43.6)
|
23.8%
|
- a Drugs being developed for rare diseases and have been designated as orphan drugs
- b Drugs being developed as biologic therapies
